Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stryker acquires Inari Medical for $80/share ... for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Also Read: Morgan Stanley Maintains Positive MedTech Outlook ...

Inari is poised to enhance Stryker's footprint ... These solutions are designed to treat peripheral vascular conditions such as pulmonary embolism and deep vein thrombosis. They claim to remove ...

Inari Medical Background Information (This ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep ...

NEW YORK, Jan 6 (Reuters) - Medical-device maker Stryker (SYK.N), opens new tab on Monday agreed to acquire Inari Medical (NARI.O), opens new tab, which makes devices that treat patients with ...

Inari shareholders are getting a fair price ... and has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia, and the like ...

Stryker Corporation's innovation and market leadership justify a premium. See why SYK stock is a solid hold with long-term ...

Inari’s product portfolio is complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and ...

Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...